Published in Rheumatology (Oxford) on July 29, 2010
Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis. PLoS One (2016) 1.38
Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.17
Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis (2013) 1.11
Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol (2015) 1.02
Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 0.87
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis (2013) 0.87
Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis. J Korean Med Sci (2014) 0.84
Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisals. Rheumatology (Oxford) (2011) 0.84
Eating disorders in adolescents with type 1 diabetes: Challenges in diagnosis and treatment. World J Diabetes (2015) 0.83
Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol (2017) 0.81
Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study. PLoS One (2014) 0.81
Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review. Clin Rheumatol (2013) 0.81
The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. BMC Musculoskelet Disord (2014) 0.80
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther (2015) 0.80
Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort. BMJ Open (2014) 0.80
[The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision]. Z Rheumatol (2017) 0.78
Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol (2016) 0.78
Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register. BMC Musculoskelet Disord (2016) 0.77
Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther (2015) 0.77
Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis (2017) 0.75
The BSRBR-RA at 15 years. Rheumatology (Oxford) (2016) 0.75
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. Rheumatology (Oxford) (2015) 0.75
Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol (2017) 0.75
The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort. Clin Rheumatol (2014) 0.75
Infliximab therapy efficacy and persistence at a Canadian academic centre despite a change in access procedure. Clin Rheumatol (2011) 0.75
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum (2005) 8.47
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol (1986) 5.82
Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) (2005) 3.56
Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) (2004) 3.50
Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. Rheumatology (Oxford) (2008) 1.59
The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ (2008) 1.58
Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis (2008) 1.48
Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis (2008) 1.33
Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol (2009) 1.28
The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) (2008) 1.22
Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol (2009) 1.21
Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis (2005) 1.19
Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2007) 1.13
Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden. Rheumatology (Oxford) (2007) 1.10
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol (2012) 4.52
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum (2007) 3.99
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum (2002) 3.53
Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. Br J Gen Pract (2007) 3.16
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) (2010) 3.04
The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int J Epidemiol (2005) 2.48
Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet (2009) 2.48
Cognitive behavior therapy, exercise, or both for treating chronic widespread pain. Arch Intern Med (2011) 2.37
Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2003) 2.20
Dietary risk factors for the development of inflammatory polyarthritis: evidence for a role of high level of red meat consumption. Arthritis Rheum (2004) 2.19
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum (2005) 2.14
Low back pain in schoolchildren: occurrence and characteristics. Pain (2002) 2.02
Modest association of joint hypermobility with disabling and limiting musculoskeletal pain: results from a large-scale general population-based survey. Arthritis Care Res (Hoboken) (2013) 2.01
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.99
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2012) 1.80
Prevalence and predictors of intense, chronic, and disabling neck and back pain in the UK general population. Spine (Phila Pa 1976) (2003) 1.79
Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol (2008) 1.78
Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2010) 1.77
No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2010) 1.73
Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum (2006) 1.72
Lateral wedge insoles as a conservative treatment for pain in patients with medial knee osteoarthritis: a meta-analysis. JAMA (2013) 1.67
Predictors of low back pain in British schoolchildren: a population-based prospective cohort study. Pediatrics (2003) 1.67
Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum (2002) 1.66
Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. Am J Epidemiol (2009) 1.60
Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol (2009) 1.60
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2012) 1.56
National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol (2003) 1.56
BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.55
Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol (2005) 1.52
Incidence of cancer among UK Gulf war veterans: cohort study. BMJ (2003) 1.43
The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis (2012) 1.30
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) (2010) 1.30
Predictors of hip joint replacement in new attenders in primary care with hip pain. Br J Gen Pract (2003) 1.29
Active exercise, education, and cognitive behavioral therapy for persistent disabling low back pain: a randomized controlled trial. Spine (Phila Pa 1976) (2007) 1.29
Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum (2004) 1.27
Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis (2006) 1.25
Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol (2007) 1.24
When should the doctor order a spine X-ray? Identifying vertebral fractures for osteoporosis care: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2004) 1.24
Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.24
Factors influencing the antibody response of dogs vaccinated against rabies. Vaccine (2007) 1.22
Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis (2009) 1.22
Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) (2013) 1.21
Cases of early inflammatory polyarthritis should not be classified as having rheumatoid arthritis. J Rheumatol (2003) 1.20
The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol (2008) 1.20
The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. Arthritis Rheum (2008) 1.18
Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum (2007) 1.16
Opportunities for prevention of 'clinically significant' knee pain: results from a population-based cross sectional survey. J Public Health (Oxf) (2004) 1.16
A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum (2004) 1.16
The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol (2005) 1.16
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther (2009) 1.15
Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis (2012) 1.14
Predicting persistent disabling low back pain in general practice: a prospective cohort study. Br J Gen Pract (2006) 1.12
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford) (2009) 1.10
Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken) (2010) 1.09
Determining aspects of ethnicity amongst persons of South Asian origin: the use of a surname-classification programme (Nam Pehchan). Public Health (2007) 1.09
Modifiable risk factors for RA: prevention, better than cure? Rheumatology (Oxford) (2011) 1.08
Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health Qual Life Outcomes (2010) 1.06
The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis Rheum (2006) 1.05
Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) (2012) 1.05
Multivariate meta-analysis of mixed outcomes: a Bayesian approach. Stat Med (2013) 1.05
The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum (2008) 1.04
BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford) (2010) 1.02
Primary care consultation predictors in men and women: a cohort study. Br J Gen Pract (2005) 1.02
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis (2012) 1.02
Association of functional outcome with both personal- and area-level socioeconomic inequalities in patients with inflammatory polyarthritis. Arthritis Rheum (2009) 1.02
Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol (2011) 1.02
Long-term mortality amongst Gulf War Veterans: is there a relationship with experiences during deployment and subsequent morbidity? Int J Epidemiol (2005) 1.01